MedTrace Logo

Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes

NCT01720303 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2017-02-20

No results posted yet for this study

Summary

This trial is conducted in Asia. The aim of this trial is to compare oral anti-diabetic drug (OAD) combined with insulin vs. insulin alone in subjects with type 2 diabetes not adequately controlled on the current OAD therapy.

Conditions

Interventions

DRUG

repaglinide

2 mg (tablets) before each main meal

DRUG

isophane human insulin

Injection s.c. (under the skin) at bedtime

DRUG

insulin

Injection s.c. (under the skin) twice daily

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-19
Primary Completion
2003-04-10
Completion
2003-04-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01720303 on ClinicalTrials.gov